胆舒胶囊治疗慢性胆囊炎疗效和安全性的Meta分析  

Efficacy and Safety of Danshu Capsule in the Treatment of Chronic Cholecystitis:A Meta-analysis

作　　者：袁雁苓[1] 张李华[1] 刘晓蓉[1] 饶凡[1] 

机构地区：[1]四川大学华西医院临床药学部,成都610041

出　　处：《中国药房》2016年第12期1645-1648,共4页China Pharmacy

摘　　要：目的:系统评价胆舒胶囊治疗慢性胆囊炎的疗效和安全性,以为临床提供循证参考。方法:计算机检索Pub Med、EMBase、Cochrane图书馆、Web of science、中国期刊全文数据库、中国生物医学文献数据库、中文科技期刊数据库和万方数据库,收集胆舒胶囊对比其他药物治疗慢性胆囊炎的随机对照试验(RCT),对符合纳入标准的研究进行资料提取,并采用Cochrane系统评价员手册5.1.0进行质量评价,采用Rev Man 5.2统计软件进行Meta分析。结果:共纳入12项RCT,合计1 140例患者。Meta分析结果显示,胆舒胶囊组患者治疗慢性胆囊炎的治愈率高于对照组,两组比较差异有统计学意义[RR=1.62,95%CI(1.33,1.96),P<0.001];胆舒胶囊组患者的总有效率高于熊去氧胆酸片组[RR=1.37,95%CI(1.14,1.64),P<0.001]、消炎利胆片组[RR=1.40,95%CI(1.24,1.58),P<0.001]、金胆片组[RR=1.13,95%CI(1.04,1.23),P=0.005]和胆宁片组[RR=1.16,95%CI(1.05,1.28),P=0.004],各组比较差异均有统计学意义。胆舒胶囊不良反应发生率低于对照组,两组比较差异有统计学意义[RR=0.20,95%CI(0.12,0.34),P<0.001]。结论:胆舒胶囊治疗慢性胆囊炎的疗效和安全性均较好。OBJECTIVE： To systematically review the efficacy and safety of Danshu capsule in the treatment of chronic chole- cystitis, and provide evidence-based reference for clinical treatment. METHODS：Retrieved from PubMed, EMBase, Cochrane Li- brary, Web of science, CJFD, CBM, VIP Database and Wanfang Database, randomized controlled trials （RCT） about Danshu capsule versus other medicines in the treatment of chronic cholecystitis were collected. Meta-analysis was performed by using Rev Man 5.2 software after data extracting and quality evaluating by Cochrane 5.1.0. RESULTS： Totally 12 RCTs were enrolled, involving 1140 patients. Results of Meta-analysis showed the cure rate of Danshu capsule in the treatment of chronic cholecystitis was higher than control group, there was statistically significant difference between 2 groups [RR=1.62,95%CI（1.33,1.96）,P〈0.001]; total effec- tive rate in Danshu capsule group was higher than Ursodeoxycholic acid tablet group[RR=1.37, 95 % CI （1.14, 1.64）, P〈0.001], Xiaoyan lidan tablet group [RR= 1.40, 95% CI （1.24, 1.58）, P〈0.001], Jindan tablet group[RR---- 1.13, 95% CI （1.04, 1.23）, P= 0.005] and Danning tablet group[RR=1.16, 95% CI（1.05, 1.28）,P=0.004], there were statistically significant differences among groups. Incidence of adverse reactions of Danshu capsule was lower than control group, there was statistically significant difference between 2 groups [RR=0.20, 95% CI （0.12,0.34）, P〈0.001]. CONCLUSIONS： Both efficacy and safety of Danshu capsule are good in the treatment of chronic cholecystitis.

关 键 词：胆舒胶囊 慢性胆囊炎 META分析 疗效 安全性 

分 类 号：R975[医药卫生—药品] R575[医药卫生—药学]